Prof. Dr. Nathan Berger
Case Western Reserve University, Cleveland, OH, USA
'%3e%3cpath%20d='M22.1642%2019.0924C21.7317%2018.068%2021.1041%2017.1375%2020.3163%2016.3527C19.5309%2015.5656%2018.6006%2014.9381%2017.5766%2014.5048C17.5674%2014.5002%2017.5582%2014.4979%2017.5491%2014.4933C18.9774%2013.4616%2019.9059%2011.7811%2019.9059%209.88504C19.9059%206.74408%2017.3611%204.19922%2014.2201%204.19922C11.0792%204.19922%208.53429%206.74408%208.53429%209.88504C8.53429%2011.7811%209.46282%2013.4616%2010.8912%2014.4956C10.882%2014.5002%2010.8728%2014.5025%2010.8636%2014.5071C9.83652%2014.9404%208.91487%2015.5617%208.1239%2016.355C7.33685%2017.1404%206.70933%2018.0707%206.276%2019.0947C5.85031%2020.0972%205.62072%2021.172%205.59967%2022.2609C5.59905%2022.2853%205.60335%2022.3097%205.61229%2022.3325C5.62123%2022.3553%205.63465%2022.376%205.65174%2022.3935C5.66883%2022.4111%205.68926%2022.425%205.71182%2022.4345C5.73437%2022.444%205.7586%2022.4489%205.78308%2022.4489H7.15868C7.25956%2022.4489%207.3398%2022.3686%207.3421%2022.2701C7.38795%2020.5001%208.09868%2018.8425%209.35506%2017.5861C10.655%2016.2862%2012.3814%2015.5709%2014.2201%2015.5709C16.0588%2015.5709%2017.7852%2016.2862%2019.0852%2017.5861C20.3415%2018.8425%2021.0523%2020.5001%2021.0981%2022.2701C21.1004%2022.3709%2021.1807%2022.4489%2021.2815%2022.4489H22.6571C22.6816%2022.4489%2022.7058%2022.444%2022.7284%2022.4345C22.751%2022.425%2022.7714%2022.4111%2022.7885%2022.3935C22.8056%2022.376%2022.819%2022.3553%2022.8279%2022.3325C22.8369%2022.3097%2022.8412%2022.2853%2022.8406%2022.2609C22.8176%2021.165%2022.5907%2020.0989%2022.1642%2019.0924ZM14.2201%2013.8284C13.1678%2013.8284%2012.1773%2013.418%2011.4322%2012.6729C10.6871%2011.9278%2010.2767%2010.9374%2010.2767%209.88504C10.2767%208.83271%2010.6871%207.84227%2011.4322%207.09715C12.1773%206.35204%2013.1678%205.94165%2014.2201%205.94165C15.2724%205.94165%2016.2629%206.35204%2017.008%207.09715C17.7531%207.84227%2018.1635%208.83271%2018.1635%209.88504C18.1635%2010.9374%2017.7531%2011.9278%2017.008%2012.6729C16.2629%2013.418%2015.2724%2013.8284%2014.2201%2013.8284Z'%20fill='%238590A2'/%3e%3c/g%3e%3c/svg%3e)
Co-authors
Following
Followers
Research Focus & Metrics
Explore full metrics on Scilit
Academic Career Length
35Years (1992-Present)
(Calculated once Scilit publication data is synced: current year − year of first publication + 1)
Representative Publications
View All Publications1 February 2021 in JAMA Oncology
Journal Article
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 and has rapidly escalated into a global pandemic.1 Severe illness of COVID-19 predominantly occurs in individuals with underlying medical comorbidities.2-5 Patients with cancer have weakened immune status; often have multiple comorbid conditions, including type 2 diabetes, obesity, and cardiovascular diseases; and are more likely to get infections.6-11 Reports from China and the US described clinical characteristics and outcomes of patients with cancer and COVID-19 and examined risk factors for mortality in this population; they suggested a higher rate of death due to COVID-19 and severe outcomes in patients with cancer.12-16 However, there is a knowledge gap regarding the susceptibility of patients with cancer to COVID-19 and its severe outcomes in the US. It remains unknown how race and other demographic factors such as age and sex affect the risk of COVID-19 infection and outcomes among patients with cancer, given that the cancer burden in the US varies by race and other demographic factors.
1 July 2024 in JAMA Network Open
Journal Article
LWLindsey Wang
Lindsey Wang
RXRong Xu
Rong XuDKDavid C. Kaelber
David C. Kaelber
Nathan BergerThirteen human malignant neoplasms have been identified as obesity-associated cancers (OAC), ie, the presence of excess body fat is associated with increased risk of developing cancer and worse prognosis in patients with these specific tumors.1 Obesity also contributes to insulin resistance and type 2 diabetes (T2D), which may further increase the risk and worsen the prognosis of the OACs.2,3
5 January 2024 in Nature Medicine
Journal Article
WWWilliam Wang
William Wang
NVNora D Volkow
Nora D VolkowNathan BergerPDPamela B. Davis
Pamela B. DavisDKDavid . Kaelber
David . KaelberRXRong Xu
Rong Xu11 April 2014 in Annals of the New York Academy of Sciences
Journal Article
Nathan BergerOverweight and obesity have reached pandemic levels on a worldwide basis and are associated with increased risk and worse prognosis for many but not all malignancies. Pathophysiologic processes that affect this association are reviewed, with a focus on the relationship between type 2 diabetes mellitus and cancer, lessons learned from the use of murine models to study the association, the impact of obesity on pancreatic cancer, the effects of dietary fats and cholesterol on cancer promotion, and the mechanisms by which the intestinal microbiome affects obesity and cancer.
1 November 2012 in Cancer Prevention Research
Journal Article
SHStephen D. Hursting
Stephen D. Hursting
JDJohn DiGiovanni
John DiGiovanni
ADAndrew J. Dannenberg
Andrew J. Dannenberg
MAMaria Azrad
Maria Azrad
DLDerek LeRoith
Derek LeRoith
Nathan Berger +3
Obesity is associated with increased risk and poor prognosis for many types of cancer. The mechanisms underlying the obesity-cancer link are becoming increasingly clear and provide multiple opportunities for primary to tertiary prevention. Several obesity-related host factors can influence tumor initiation, progression and/or response to therapy, and these have been implicated as key contributors to the complex effects of obesity on cancer incidence and outcomes. These host factors include insulin, insulin-like growth factor-I, leptin, adiponectin, steroid hormones, cytokines, and inflammation-related molecules. Each of these host factors is considered in the context of energy balance and as potential targets for cancer prevention. The possibility of prevention at the systems level, including energy restriction, dietary composition, and exercise is considered as is the importance of the newly emerging field of stem cell research as a model for studying energy balance and cancer prevention. Cancer Prev Res; 5(11); 1260–72. ©2012 AACR.
1 February 2024 in JAMA Oncology
Journal Article
LWLindsey Wang
Lindsey Wang
WWWilliam Wang
William Wang
DKDavid C. Kaelber
David C. Kaelber
RXRong Xu
Rong XuNathan BergerGlucagon-like peptide 1 receptor agonists (GLP-1RAs) are approved by the US Food and Drug Administration for treating type 2 diabetes (T2D). GLP-1RAs have pleiotropic effects on lowering plasma glucose, inducing weight loss, and modulating immune functions.1 Because overweight/obesity is a major risk factor for colorectal cancer (CRC),2 we hypothesize that GLP-1RAs are associated with a decreased risk for CRC in patients with T2D compared with non–GLP-1RA antidiabetics. We conducted a nationwide, retrospective cohort study among drug-naive patients with T2D comparing GLP-1RAs with 7 non–GLP-1RA antidiabetics, including metformin and insulin, which are suggested to influence CRC risk.3
About Me
Dr. Nathan A. Berger is the Hanna-Payne Professor of Experimental Medicine and Director of the Center for Science, Health, and Society at Case Western Reserve University School of Medicine. He is a Professor of Medicine, Biochemistry, Oncology, and Genetics and a CWRU Distinguished University Professor. From 1968 to 1971, he served as a Lieutenant Commander in the United States Public Health Service and a Research Associate at the NIH, NICHD Gerontology Research Center, Laboratory of Molecular Biology, Baltimore, Maryland. He completed a fellowship in Hematology and Oncology at Washington University School of Medicine, St. Louis, Missouri, and joined the faculty there before moving to Case Western Reserve University School of Medicine in Cleveland, Ohio, as Professor of Medicine and Biochemistry and Director of the Hematology and Oncology Division. He became the Founding Director of the Case Western Reserve University/Ireland Cancer Center, which was awarded NCI Cancer Center status in 1987 and subsequently designated an NCI Comprehensive Cancer Center. He was Dean of Case Western Reserve University School of Medicine from 1995 to 2002. His current research focuses on Transdisciplinary Studies in Energy Balance and Cancer and critical aspects of the relationship between Aging and Cancer.